Exploring the vicinity of the Bogomol'nyi-Prasad-Sommerfield bound

We investigate systems of real scalar fields in bidimensional spacetime, dealing with potentials that are small modifications of potentials that admit supersymmetric extensions. The modifications are controlled by a real parameter, which allows implementing a perturbation procedure when such parameter is small. The approach allows obtaining the energy and topological charge in closed forms, up to first order in the parameter. We illustrate the procedure with some examples. In particular, we show how to remove the degeneracy in energy for the one-field and the two-field solutions that appear in a model of two real scalar fields.Comment: Revtex, 9 pages, To be published in J. Phys.

Tiling the plane without supersymmetry

We present a way of tiling the plane with a regular hexagonal network of defects. The network is stable and follows in consequence of the three-junctions that appear in a model of two real scalar fields that presents $Z_3$ symmetry. The $Z_3$ symmetry is effective in both the vacuum and defect sectors, and no supersymmetry is required to build the network.Comment: Revtex, 4 pages, 1 ps figure; version to appear in Phys. Rev. Let

Bags, junctions, and networks of BPS and non-BPS defects

We investigate several models of coupled scalar fields that present discrete Z_2, Z_2 x Z_2, Z_3 and other symmetries. These models support topological domain wall solutions of the BPS and non-BPS type. The BPS solutions are stable, but the stability of the non-BPS solutions may depend on the parameters that specify the models. The BPS and non-BPS states give rise to bags, and also to three-junctions that may allow the presence of networks of topological defects. In particular, we show that the non-BPS defects of a specific model that engenders the Z_3 symmetry give rise to a stable regular hexagonal network of domain walls.Comment: Revtex, 16 pages, 6 ps figures; Shorter version to be published in Phys. Rev.

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None